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Synopsis
Compound 21 (C21), selective agonist of angiotensin type-2 (AT-2) receptors, shows anti-inflammatory effects in
experimental models of hypertension and nephroprotection in diabetes. The aim of the present study was to evaluate
the effects of C21 in cyclosporine nephropathy, which is characterized mainly by tubulo-interstitial fibrosis. Ten days
before and during the experimental periods, low-salt diet was administered to Sprague–Dawley rats. Cyclosporine-A
(CsA; 15 mg/kg per day, intraperitoneal injection) and CsA plus C21 (0.3 mg/kg per day, intraperitoneal injection) were
administered for 1 and 4 weeks. Control groups were left without any treatment. Blood pressure (plethysmographic
method) and 24 h urinary albumin excretion were measured once a week. At the end of the experimental protocols,
the kidneys were excised for histomorphometric analysis of renal fibrosis and for immunohistochemical evaluation
of inflammatory infiltrates and type I and type IV collagen expression. After 1 and 4 weeks, the rats treated with
CsA showed a significant increase (P<0.01) in blood pressure, no significant changes in urinary albumin excretion
and a significant increase (P<0.01) in glomerular and tubulo-interstitial fibrosis and inflammatory infiltrates as
compared with the control rats. Treatment with C21 did not modify the CsA dependent increase of blood pressure,
which was higher than in control rats, but after 4 weeks of treatment significantly reduced (P<0.01) glomerular and
tubulo-interstitial fibrosis, type 1 collagen expression and macrophage infiltration, as compared with rats treated with
cyclosporine. The administration of C21 showed a protective effect on cyclosporine nephropathy, decreasing renal
fibrosis and macrophage infiltration. These data suggest that C21 may counteract tubulo-interstitial fibrosis, the most
potent predictor of the progression of renal diseases.
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renal fibrosis.
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INTRODUCTION
Renal fibrosis represents a serious complication of chronic kidney
diseases, leading to end-stage renal failure, independently on the
aetiology of initial renal injury [1].
The increase in collagen and extracellular matrix protein de-
position in glomerular and tubulo-interstitial area, modulated by
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multiple molecular pathways, characterizes the progression of
renal fibrosis [2,3].
Generally, in the development of renal fibrosis it is recog-
nized an initial increase in the synthesis of growth factors and
cytokines by resident cells, accompanied by the influx of inflam-
matory cells, monocyte-macrophages, which further promotes
the release of cytokines and matrix proteins [3]. These altera-
tions are followed by an excessive deposition of extracellular
c© 2016 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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matrix proteins and by an abnormal process of matrix remodel-
ling, which leads to the formation of renal scarring and finally to
organ failure [4].
Despite the evidence that the fibrotic processes may affect all
the renal districts, tubulo-interstitial fibrosis represents the most
potent predictor of outcome in renal diseases [5,6].
Cyclosporine-A (CsA) is a calcineurin inhibitor widely used
for many years in organ transplantation [7]. CsA treatment has im-
proved the survival in transplanted patients, but its use is burdened
by side effects such as hypertension and nephrotoxicity [8–11].
Immunosuppressive medications, particularly CsA treatment, are
associated with post-transplant hypertension, which is a common
clinical problem in transplanted patients [12], increasing cardi-
ovascular mortality and morbility.
Chronic CsA nephropathy is a major cause of chronic allograft
dysfunction and allograft failure in renal transplant recipients
[8] and is characterized by tubular atrophy, inflammatory cell
infiltration and hyalinosis of the afferent arterioles, followed by
the development of tubulo-interstitial fibrosis.
Renin–angiotensin–aldosterone system is an important regu-
lator of renal and myocardial fibrosis, and drugs interfering with
the renin–angiotensin–aldosterone system, as angiotensin con-
verting enzyme (ACE) inhibitors and angiotensin type 1 receptor
blockers, presently represent the tools of choice to counteract the
progression of renal and cardiovascular diseases [13].
Angiotensin II (Ang II), the main effector of the renin–
angiotensin system, binds two membrane G-protein-coupled re-
ceptors, AT-1 and AT-2 receptors. The majority of the negative
haemodynamic (vasoconstriction and hypertension) and cellular
(collagen synthesis, collagen deposition and cytokine production)
[14–16] effects of Ang II is mediated by the renin/ACE/Ang II–
AT-1 receptor axis, the well-established target of ACE-inhibitors
and angiotensin type 1 receptor blockers. On the contrary, it
has been shown that the activation of the angiotensin type-
2 (AT-2) receptors can counterbalance some of the actions
mediated by AT-1 receptors, resulting in a significant organ
protection [17–19].
Compound 21 (C21), a nonpeptide, highly selective AT-2
receptor agonist [20], directly stimulates the AT-2 receptors,
thus representing an important new tool to investigate the AT-
2 receptor-mediated effects.
Increasing data demonstrate that C21 has positive effects in
the cardiovascular system, it actually improves the cardiac func-
tion in rat with myocardial infarction [21,22], and reduces the
cardiovascular fibrosis both in stroke-prone spontaneously hy-
pertensive rats [23], and in an experimental model of Nω-nitro-
l-arginine-methyl ester-induced hypertension [24].
In the kidney, C21 administration blunts renal inflammatory
cell infiltration in renovascular hypertension [25] and in stroke
prone spontaneously hypertensive rats [23,26], showing nephro-
protective effects in obese Zucker rats [27,28] and in diabetic
nephropathy [29,30].
The aim of the present study was to investigate the effect of
C21 administration on CsA nephropathy. The effect of C21 ad-




Animal husbandry was in conformity with the Institu-
tional Guidelines in compliance with National laws and
policies (D.L.n. 116, Gazzetta Ufficiale della Repubblica Itali-
ana, suppl. 40, Feb. 18, 1992) and experiments were per-
formed in accordance with the Guide for the Care and
Use of Laboratory Animals published by the US National
Institutes of Health (NIH Publication No. 85-23, revised
1996).
Conscious male Sprague–Dawley rats, 150–200 g body weight
(BW; Charles River), were individually housed in cages (or
metabolic cages as necessary to collect 24 h urine samples) in
a temperature-controlled room (22 ◦C) with a 12:12 light–dark
cycle and free access to low-salt diet (Teklad 7034) and tap wa-
ter. Low-salt diet was used to increase renal cyclosporine damage
[31,32].
BW (g) and systolic blood pressure (SBP, mmHg) were meas-
ured at the beginning and weekly during the experimental period
by the tail cuff method (average of six recordings. BP Recorder,
Ugo Basile Instruments) by an investigator who was unaware of
the specific treatments.
To induce nephropathy, cyclosporine-A (Sandimmun, No-
vartis) was administered at the dose of 15 mg/kg per day
by intraperitoneal injection for 8 days (short-term treatment)
and for 28 days (long-term treatment). C21 (Vicore Pharma)
was administered at the dose of 0.3 mg/kg per day by in-
traperitoneal injection. The dose used was chosen based on
the demonstration of efficacy on tissue remodelling in pre-
vious experimental studies [19,21,24,25,29]. To evaluate the
effects of short-term treatment (8 days) a group of 18 rats
were studied (control, n = 5; CsA-treated rats, n = 6;
CsA + C21-treated rats, n = 7). A group of 24 rats (control,
n = 8; CsA-treated rats, n = 8; CsA + C21 treated-rats, n =
8) were studied to evaluate the effects of long-term treatment
(28 days). At the end of the experimental periods, blood samples
were collected to measure creatinine (Cobas Mira Plus Instru-
ment, Roche), then the rats were killed with an overdose of
anaesthesia (sodium pentobarbital). Urinary albumin excretion
was measured at the beginning and at the end of experimental
periods, on 24 h urine collections by Elisa (Nephrat II Elisa,
Exocell). After the sacrifice, kidneys and hearts were immedi-
ately excised and weighted. Kidneys transmural sections were
fixed with 10% formalin, embedded in paraffin and used for
light microscopic examination, morphometric analysis of glom-
erular, tubulo-interstitial and perivascular fibrosis and mono-
cyte/macrophage, type I and type IV collagen immunostaining.
The apex of the heart was cut, frozen in liquid nitrogen and
stored at − 80 ◦C until RNA extraction. The heart was sec-
tioned into three transverse slices from the apex to the base,
fixed with 10% formalin, embedded in paraffin and used for
light microscopic examination and morphometric analysis of in-
terstitial and perivascular collagen and monocyte/macrophage
immunostaining.
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Compound 21 and cyclosporine nephropathy
Histological analysis and morphometric evaluation
of renal and myocardial fibrosis
For all rats renal transmural sections (4 μm) and coronal car-
diac sections (4 μm) were deparaffinized, rehydrated and stained
with haematoxylin–eosin (H&E), following standard techniques.
Changes in renal and cardiac morphology were assessed by light
microscopic analysis of sections. For all rats a renal consecutive
section (4 μm) and a coronal cardiac section (4 μm) were also
stained with collagen-specific sirius red and used for morpho-
metric analysis of renal and myocardial fibrosis, as previously
described [33,34]. Briefly, slides were examined with a Leica
microscope (Leitz Camera) using normal light. A computerized
digital camera (Olympus Camedia 5050, Olympus) was used to
capture 5 Mp (24-bit colour depth) images (stored as JPG files)
and analysed for renal collagen volume fraction in glomerular,
tubulo-interstitial and perivascular areas and in interstitial and
perivascular cardiac areas with a computerized imaging software
(ImageJ, NIH). Two pathologists, blinded to the experimental
protocol, performed image analysis.
Glomerular and tubulo-interstitial collagen volume fractions
were evaluated at ×200 magnification, respectively, in semi-
automated fashion in 10 traced glomeruli (considered as mat-
rix, cells, capillary loops and space surrounding glomerular seg-
ments) and in automated fashion in 10 fields without vessels or
glomeruli, randomly selected from each kidney section.
The glomerular collagen fraction was expressed as the ra-
tio between red-stained collagen area and glomerular area; the
tubulo-interstitial collagen fraction was expressed as the ratio
between collagen area and total area.
For analysis of perivascular fibrosis, 10 vessels were randomly
selected at ×400 magnification from each kidney section. The im-
age analysis of intraparenchimal vessels was performed in semi-
automated fashion. Only the collagen immediately surrounding
each intraparenchimal vessel was considered to represent pe-
rivascular collagen deposition. The perivascular collagen volume
fraction was expressed as the ratio between collagen area sur-
rounding the traced vessel and total cross-sectional area, in order
to correct differences in vessel size.
Myocardial total collagen volume fraction was measured on
10 randomly selected microscopic fields of the left ventricular
(LV) coronal slice (×200 magnification) and was automatically
calculated as the ratio between red-stained interstitial area and
the total area of the heart section. For analysis of the perivascular
collagen volume fraction, five randomly selected vessels from
LV coronal slice were traced and semi-automatically measured
(×400 magnification). The collagen immediately surrounding
each intramyocardial vessel was considered to represent perivas-
cular collagen deposition and expressed as the ratio between
perivascular collagen area and luminal media area [33].
Immunohistochemical evaluation of
monocyte/macrophage renal and myocardial
infiltration
The evaluation of monocytes/macrophages infiltration was per-
formed on formalin fixed and paraffin embedded renal and
heart sections (3 μm) using a monoclonal mouse anti-rat mono-
cytes/macrophage (CD68, Chemicon), as previously described
[29]. The sections were deparaffinized and rehydrated, treated by
boiling in citrate buffer (0.01 mol/l, pH 6) in microwave (750
W), and incubated over night at 4 ◦C with primary antibody
(1:300). Ultra Tek HRP (Anti-Mouse) Staining System (Scy TeK
Laboratories) was used to label the primary antibody. The reac-
tion product was visualized with 3,3’-diaminobenzidine (DAB)
(Dako). Negative control was obtained by omitting the primary
antibody. Sections were viewed using a Leica microscope (Leitz
Camera), and digital images were taken using a computerized
digital camera (Olympus Camedia 5050, Olympus). Two inde-
pendent pathologists blinded to the treatment counted the positive
cells in 10 randomly selected non-overlapping fields per section
at ×200 magnification and took the average. The macrophages
were expressed as number of positive cells/fields [29].
Type I collagen and type IV collagen
immunohistochemistry
Immunohistochemical evaluation was performed on consecut-
ive sections (3 μm) of formalin fixed, paraffin embedded renal
tissue. Sections were deparaffinized in xylene and rehydrated
through graded alcohol series. Endogenous peroxidase activ-
ity was blocked by 3% hydrogen peroxide. The sections were
treated with microwave (pH 6 citrate buffer). The sections were
then incubated at 4 ◦C overnight with type I collagen (1:300, rab-
bit anti-rat polyclonal antibody, Millipore Chemicon, AB755P)
or type IV collagen (1:150, rabbit anti-human polyclonal an-
tibody, Abcam, AB6586). The reaction was amplified with
LSAB2 + System-HRP, as previously described [9]. A posit-
ive immunoreaction was identified after incubation with DAB
and counterstaining with Mayer haematoxylin. Negative con-
trols were obtained omitting the primary antibody. Sections were
viewed using a Leica microscope (Leitz Camera). Two inde-
pendent pathologists, blinded to the treatment, analysed the im-
munostaining with a Leica microscope (Leitz Camera) and, sub-
sequently, for each rat, 5-Mp (24-bit colour depth) images of
glomerular and tubulo-interstitial area (20× objective) were cap-
tured by a computerized digital camera (Olympus Camedia 5050,
Olympus). Immunostaining was quantified by a pathologist, us-
ing a computerized imaging software (ImageJ, NIH), respect-
ively, in semi-automated fashion in 10 traced glomeruli and in
automated fashion in 10 tubulo-interstitial fields (without ves-
sels or glomeruli), randomly selected from each kidney section.
Type 1 and type IV collagen immunostaining was expressed as
percentage (ratio of immunostaining area to total area or glom-
erular area) [35].
Myocardial collagen analysis by polarized light
microscope
Sirius Red-stained myocardial coronal section was also analysed
in the long-term protocol using a light microscope under po-
larized light to evaluate the different types of collagen in in-
terstitial and perivascular areas. By polarized light microscope,
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Table 1 SBP (mmHg), BW (g), kidney/BW ratio (mg/g), heart/BW ratio (mg/g), GFR (ml/min),
urinary albumin excretion (UAE, mg/24 h) in control, CsA and CsA+C21-treated rats at the end
of 8 days of treatment
*P<0.01 compared with control group.
Control CsA CsA+C21
SPB, mmHg 140.1+−2.2 176.2+−2.8* 174.2+−2.5*
BW, g 384.75+−13.48 335.16+−5.51* 341.71+−8.42*
Kidney/BW, mg/g 3.905+−0.169 3.879+−0.098 4.005+−0.089
Heart/BW, mg/g 3.192+−0.116 2.958+−0.073 3.194+−0.075
GFR, ml/min 1.716+−0.241 1.681+−0.248 1.663+−0.262
UAE, mg/24 h 1.53+−0.62 1.89+−0.30 1.58+−0.73
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Figure 1 Effect of C21 administration for 8 days on renal fibrosis in CsA-treated rats
Panel 1: Representative photomicrographs of glomerular, tubulo-interstitial and perivascular fibrosis in control (a, d, g),
CsA (b, e, h), CsA+C21-treated (c, f, i) rats (sirius red staining: glomerular and tubulo-interstitial fields, ×20; perivascular
fields, ×40). Staining showed an increase in glomerular and tubulo-interstitial fibrosis in CsA-treated rats (b and e) as
compared with control rats (a and d). C21 treatment (c and f) did not modify glomerular and tubulo-interstitial fibrosis in
CsA-treated rats. Perivascular fibrosis did not change both in CsA-treated rats (h) and CsA+C21-treated rats (i). Panel 2:
Quantification of glomerular, tubulo-interstitial and perivascular fibrosis in the different groups of rats. Data are means +−
S.E.M. *P<0.01 compared with control group.
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Figure 2 Effects of C21 administration for 8 days on renal inflammatory cell infiltration in CsA-treated rats
Panel 1: Immunohistochemical identification of renal inflammatory cell infiltration in control (a), CsA-treated rats (b) and
CsA+C21-treated rats (c) (original magnification ×20). The immunostaining showed a significant increase in interstitial
monocyte/macrophage cells (brown reaction) in CsA-treated rats (b) as compared with control rats (a). C21 administration
did not modify the increase of monocyte/macrophage infiltration in CsA-treated rats (c). Panel 2: Quantification of staining
of renal monocyte/macrophage inflammatory cells in the different groups of rats. Data are means +− S.E.M. *P<0.01
compared with control group.
collagen type I appears yellow/orange, whereas collagen type III
presents as green [36]. For each rat, randomly selected micro-
scopic fields of interstitial and perivascular areas were analysed
with polarized light microscope using a 20× objective (Leiz
Camera). Images were captured by a computerized digital cam-
era (Olympus Camedia 5050, Olympus) and analysed for dif-
ferent type of collagen by the same pathologists, as previously
described [33].
Total RNA extraction, reverse transcription and
myocardial Col1A1 and fibronectin mRNA
expression
Total RNA was extracted from the heart using Mirvana Kit (Am-
bion, Lifetechnologies), following the manufacturer’s instruc-
tions. One microgram of RNA was reverse-transcribed to syn-
thesize cDNA (High Capacity cDNA Reverse Transcription kit,
Applied Biosystems).
Myocardial mRNA expression of collagen 1A1 (Col1A1),
fibronectin (FN-1) and glyceraldehyde-3-phosphate dehydro-
genase (GAPDH), used as reference gene, was evaluated
by real-time PCR using the TaqMan Realtime ABI Prism
7900 HT Sequence Detection System (Applied Biosystems).
Col1A1, FN-1 and GAPDH mRNA expression were evaluated
using the Assay-on-Demand Gene Expression Product (Ap-
plied Biosystems), following the manufacturer’s instructions.
All reactions were performed in duplicate. Expression levels
were normalized to GAPDH mRNA expression, following the
2− Ct [35].
Statistical analysis
Data are presented as means +− S.E.M. Differences among the
groups of rats (control, CsA and CsA + C21-treated rats) for SBP,
BW, kidney/BW, heart/BW, glomerular filtration rate (GFR), 24 h
urinary albumin excretion, renal glomerular, tubulo-interstitial
and perivascular fibrosis, myocardial interstitial and perivascular
fibrosis, renal inflammatory infiltrates and type I and type IV
collagen expression, and myocardial Col1A1 and FN-1 mRNA
expression were assessed with the use of ANOVA followed by
the Fisher’s protected least-significant test for post-hoc compar-
isons. Differences between means were considered significant at
P < 0.05.
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Figure 3 Effects of C21 administration for 8 days on myocardial fibrosis in CsA-treated rats
Panel 1: Representative photomicrographs of perivascular and interstitial fibrosis and inflammatory cell infiltration in left
ventricle of control (a and d), CsA-treated (b and e) and CsA+C21-treated rats (c and f). Sirius red staining: interstitial
fields, original magnification ×20; perivascular fields, original magnification ×40. Sirius red staining did not show changes
in myocardial fibrosis, both at perivascular and interstitial area in CsA-treated rats (b and e) and CsA+C21-treated rats (c
and f). Immunohistochemical staining of myocardial inflammatory cell infiltration showed a significant increase in interstitial
monocyte/macrophage cells in CsA-treated rats (h) compared with control rats (g). C21 administration did not modify the
increase of monocyte/macrophage infiltration in CsA-treated rats (i). Panel 2: Quantification of myocardial perivascular
and interstitial fibrosis and monocyte/macrophage inflammatory cells in the different groups of rats. Data are means +−
S.E.M. *P<0.01 compared the control group.
RESULTS
Short-term protocol
Effects of chronic short-term C21 treatment on systolic
blood pressure, glomerular filtration rate and urinary
albumin excretion in CsA-treated rats
Table 1 shows the effects of chronic short-term C21 adminis-
tration on SBP, BW, kidney/BW, heart/BW, GFR and urinary
albumin excretion in CsA-treated rats.
After 8 days of treatment, SBP was significantly higher in
the CsA-treated rats and CsA + C21-treated rats compared with
the control animals. C21 did not modify the increase of blood
pressure in CsA-treated rats.
BW was significantly reduced in CsA-treated and CsA + C21-
treated rats with respect to control rats (Table 1). Kidney
weight/BW ratio and heart weight/BW ratio were similar among
the groups (Table 1). CsA and C21 treatment for 8 days did not
modify GFR and urinary albumin excretion as compared with
control rats (Table 1).
Effects of chronic short-term C21 treatment on renal
fibrosis and inflammatory cell infiltration
At the end of the experimental period, histologic examination
showed focal dilatation of cortical tubules and a greater number
of interstitial monocytic cells in CsA and CsA + C21 treated rats
with respect to control rats.
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Compound 21 and cyclosporine nephropathy
Table 2 BW (g), kidney/BW ratio (mg/g), heart/BW ratio (mg/g), GFR (ml/min), urinary albumin
excretion (UAE, mg/24 h) in control, CsA, and CsA+C21-treated rats at the end of 28 days of
treatment
*P<0.01 compared with control group.
Control CsA CsA+C21
BW, g 401.42+−2.02 368.65+−8.58* 360.66+−7.52*
Kidney/BW, mg/g 3.929+−0.145 3.902+−0.108 4.130+−0.083
Heart/BW, mg/g 2.927+−0.134 2.942+−0.048 3.129+−0.121
GFR, ml/min 2.788+−0.899 2.040+−0.290 2.929+−0.624
UAE, mg/24 h 2.13+−0.45 2.65+−0.42 2.08+−0.23
The morphometric analysis showed a significant increase in
glomerular and tubulo-interstitial fibrosis, quantified by com-
puterized image analysis after sirius red staining, in CsA-
treated rats, whereas perivascular fibrosis was not modi-
fied (Figure 1, Panels 1 and 2). Administration of C21
for 8 days did not modify the increase in glomerular and
tubulo-interstitial fibrosis in CsA-treated rats (Figure 1,
Panels 1 and 2).
Similarly to what observed for the fibrosis, CsA
administration caused a significant increase in mono-
cyte/macrophage infiltration in renal tissue when compared
with control rats (Figure 2, Panels 1 and 2). C21 ad-
ministration did not modify the increase in monocyte/
macrophage infiltration caused by CsA treatment (Figure 2,
Panels 1 and 2).
Effects of chronic short-term C21 treatment on
myocardial fibrosis and inflammatory cell infiltration
The evaluation of myocardial fibrosis after sirius red staining
is shown in Figure 3. Both CsA treatment and C21 administra-
tion for 8 days did not significantly modify myocardial fibrosis
both at perivascular and interstitial area (Figure 3, Panels 1 and
2). Differently, CsA administration caused a significant increase
in monocyte/macrophage infiltration in myocardial tissue when
compared with control rats (Figure 3, Panels 1 and 2). C21 admin-
istration did not modify the increase in monocyte/macrophage
infiltration caused by CsA treatment (Figure 3, Panels 1 and 2).
Long-term protocol
Effects of chronic long-term C21 treatment on systolic
blood pressure, glomerular filtration rate and urinary
albumin excretion in CsA-treated rats
Figure 4 shows the effects of chronic long-term C21 adminis-
tration on SBP during the experimental period. SBP was signi-
ficantly higher in the CsA-treated rats and CsA + C21-treated
rats compared with the control animals during the entire experi-
mental period, starting from the first week of the treatment. C21
did not modify the increase of blood pressure in CsA-treated rats
(Figure 4)
Table 2 shows the effects of chronic long-term C21 adminis-
tration on BW, kidney/BW, heart/BW, GFR and urinary albumin
























Figure 4 Time course of blood pressure in CsA nephropathy be-
fore and during C21 administration
Control, continuous line; CsA, dotted line; CsA+C21-treated rats,
dashed line. *P<0.01 compared with corresponding basal values and
control group.
BW was significantly reduced in CsA-treated and CsA + C21-
treated rats with respect to control rats (Table 2). Kidney
weight/BW ratio and heart weight/BW ratio were similar among
the groups. (Table 2). GFR and urinary albumin excretion did
not show significant changes among the groups, even if a slight
decrease in GFR in CsA-treated rats was observed (Table 2).
Effects of chronic long-term C21 treatment on renal
fibrosis, type I and type IV collagen, and inflammatory
cell infiltration
In the kidney, morphologic examination showed dilated cortical
tubules and the presence of interstitial inflammatory cells in CsA
and CsA + C21-treated rats.
Glomerular and tubulo-interstitial fibrosis were significantly
increased in CsA-treated rats (Figure 5, Panels 1 and 2), whereas
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Figure 5 Effect of C21 administration for 28 days on renal fibrosis in CsA-treated rats
Panel 1: Representative microscopic images of glomerular, tubulo-interstitial and perivascular fibrosis in control (a, d, g),
CsA (b, e, h), CsA+C21-treated (c, f, i) rats (sirius red staining: glomerular and tubulo-interstitial fields, original magnifica-
tion ×20; perivascular fields, original magnification ×40). Staining showed an increase in glomerular and tubulo-interstitial
fibrosis in CsA-treated rats (b and e) as compared with control rats (a and d). C21 treatment (c and f) reduced glomerular
and tubulo-interstitial fibrosis in CsA-treated rats. Perivascular fibrosis did not change both in CsA-treated rats (h) and
CsA+C21-treated rats (i). Panel 2: Quantification of glomerular, tubulo-interstitial and perivascular fibrosis in the different
groups of rats. Data are means +− S.E.M. *P<0.01 compared with control group; δP<0.01 compared with CsA-treated
rats
perivascular fibrosis was not modified. Administration of C21
for 28 days blunted the increase in glomerular fibrosis in CsA-
treated rats, which remained higher compared with control rats
(Figure 5, Panels 1 and 2). Administration of C21 for 28 days
caused a significant reduction in tubulo-interstitial fibrosis in
CsA-treated rats (Figure 5, Panels 1 and 2), toward values
similar to control rats. CsA administration caused a signi-
ficant increase in type I collagen at tubulo-interstitial level,
blocked by C21 treatment, whereas type IV collagen at glom-
erular level did not significantly changed (Figure 6, Panels 1
and 2).
CsA administration caused a significant increase in mono-
cyte/macrophage infiltration in renal parenchyma, localized in
the tubulo-interstitial area, when compared with control rats
(Figure 6, Panels 1 and 2). C21 administration completely
blocked inflammatory cell infiltration caused by CsA adminis-
tration (Figure 6, Panels 1 and 2).
Effects of chronic long-term C21 treatment on
myocardial fibrosis, type 1 collagen and fibronectin
mRNA expression and inflammatory cell infiltration
Figure 7 shows the evaluation of myocardial fibrosis after sirius
red staining with corresponding analysis of collagen fibres by
polarized light microscope. CsA treatment for 28 days signi-
ficantly increased myocardial fibrosis both at perivascular and
interstitial area (Figure 7, Panels 1 and 2). C21 administration
blunted the development of myocardial fibrosis in myocardial
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Compound 21 and cyclosporine nephropathy
Figure 6 Effects of C21 administration for 28 days on type I and type IV collagen and inflammatory cell infiltration in
the kidney of CsA-treated rats
Panel 1: Representative photomicrographs of immunohistochemical characterization of renal type I and type IV collagen
and inflammatory cell infiltration in control (a, d, g), CsA-treated rats (b, e, h), and CsA+C21-treated rats (c, f, i). The
immunostaining (brown reaction, 20×) showed a significant increase in interstitial type I collagen in CsA-treated rats
(b) compared with control rats (a). C21 administration reduced the increase of type I collagen in CsA-treated rats (c).
Type IV collagen in glomerular area did not modify in CsA (e) and CsA+C21-treated (f) rats respect to control rats (d). CsA
treatment caused an increase in monocyte/macrophage cell infiltration in CsA-treated rats (h) as compared with control
rats (g). C21 administration reduced the increase of monocyte/macrophage cell infiltration in CsA-treated rats (i). Panel
2: Quantification of staining of renal type I collagen, type IV collagen and monocyte/macrophage inflammatory cells in
the different groups of rats. Data are means +− S.E.M. *P<0.01 compared with control rats, δP<0.01 compared with
CsA-treated rats.
tissue, mainly at interstitial level (Figure 7, Panels 1 and 2). The
analysis with polarized light microscope shows that perivascular
and interstitial fibrosis (Figure 7, Panel 1) is due to a prevalent
increase of type I collagen (orange stain). CsA administration
caused a significant increase in monocyte/macrophage infiltra-
tion in myocardial tissue when compared with control rats (Fig-
ure 7, Panels 1 and 2). C21 administration blocked the increase
in monocyte/macrophage infiltration caused by CsA treatment
(Figure 7, Panels 1 and 2).
In the hearts of CsA-treated rats Col1A1 and FN-1 mRNA
expression, evaluated by quantitative real time PCR, were sig-
nificantly increased as compared with control rats (Figure 8).
C21 administration completely blocked the increase in Col1A1
and FN-1 mRNA expression in the hearts of CsA-treated rats
(Figure 8).
DISCUSSION
The results of the present study demonstrate that chronic C21
treatment promotes nephroprotection in CsA nephropathy, by re-
ducing renal fibrosis and inflammatory cell infiltration, in absence
of blood pressure modifications.
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Figure 7 Effects of C21 administration for 28 days on myocardial fibrosis and monocyte/macrophage cell infiltration in
CsA-treated rats
Panel 1: Representative photomicrographs of the LV perivascular and interstitial fibrosis and inflammatory cell infiltration in
control (a, d, g), CsA-treated (b, e, h) and CsA+C21-treated rats (c, f, i). Sirius red staining showed an increase in myocar-
dial fibrosis, both at perivascular (×40) and interstitial (×20) area in CsA-treated rats (b and e) and CsA+C21-treated rats
(c and f) as compared with control rats (a and d). C21 treatment caused a significant decrease in interstitial fibrosis (f)
respect to CsA-treated (e) rats. The polarized light analysis showed the prevalence of type I collagen fibres (yellow/orange)
in the heart of all the rat groups. Representative photomicrographs of immunohistochemical characterization of myocardial
inflammatory cell infiltration (×20) (g, h, i). There was a significant increase in interstitial monocyte/macrophage cells
(brown reaction) in CsA-treated rats (h) as compared with control rats (g). C21 administration reduced the increase of
monocyte/macrophage infiltration in CsA-treated rats (i), as compared with CsA-treated rats. Panel 2: Quantification
of myocardial perivascular and interstitial fibrosis and monocyte/macrophage inflammatory cells in the different groups of
rats. Data are means +− S.E.M. *P<0.01 compared with control group. δP<0.01 compared with CsA-treated rats.
CsA administration, after both 1 and 4 weeks, caused an in-
crease in blood pressure and renal fibrosis at glomerular and
tubulo-interstitial area, but not at perivascular level, and an
increase in inflammatory cell infiltration. C21 treatment for
1 week did not modify the increase of blood pressure caused
by CsA administration and did not show any effect on glom-
erular and tubulo-interstitial fibrosis and monocyte-macrophage
infiltration.
After 4 weeks, C21 treatment did not modify the increase of
blood pressure caused by CsA administration, whereas reduced
glomerular and tubulo-interstitial fibrosis and blocked inflam-
matory cell infiltration.
CsA nephropathy is predominantly characterized by tubulo-
interstitial fibrosis, with evidence of fibrotic stripes in the inter-
stitial space and tubular damage [8].
Our data confirm the characteristics of these lesions, but using
computerized image quantification techniques, we were able to
detect the presence of fibrosis also in the glomerular area, al-
though of lesser degree respect to the tubulo-interstitium. After
4 weeks of treatment, the antifibrotic effect of C21 is also present
at the glomerular area, but it is stronger at tubulo-interstitial level,
where not only significantly reduces fibrosis compared with the
CsA-treated group, but also brings to values not different com-
pared with the control group.
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Figure 8 Effect of CsA and C21 administration on collagen 1A1 (Col1A1) and fibronectin (FN-1) mRNA expression in the
heart by real-time PCR
Data are means +− S.E.M. *P<0.01 compared with control group. δP<0.01 compared with CsA-treated rats.
The administration of CsA caused an increase in inflammatory
infiltrates, which is predominantly localized at tubulo-interstitial
level. C21 treatment for 4 weeks markedly reduced the inflam-
matory cell infiltration, supporting the notion that the antifibrotic
effect of C21 is mediated by an anti-inflammatory action.
As occurs also in patients [11], CsA treatment caused an
increase in blood pressure that was not changed by C21 ad-
ministration. Furthermore, the C21 antifibrotic effect, observed
in the kidney, is independent on changes in blood pressure
level.
At difference with the kidney, the development of cardiac
fibrosis appears to be delayed. In fact, myocardial fibrosis, both
at perivascular and interstitial level, was not observed after
1 week of CsA administration, when inflammatory cell infilt-
rates were already present, a dysfunction that persisted after
4 weeks.
After 4 weeks, CsA caused a significant increase in myocardial
fibrosis, both at perivascular and interstitial level, associated with
an increase of inflammatory infiltrates.
At difference with the kidney, where perivascular fibrosis was
undetectable, in the heart perivascular fibrosis was stronger than
interstitial fibrosis after CsA administration.
In CsA-treated rats C21 significantly reduced myocardial in-
terstitial fibrosis, blocking the inflammatory cell infiltration, but
did not significantly reduce perivascular fibrosis, even if it was a
trend to a reduction.
Although there are common features between the renal and
cardiac fibrosis, our findings support the hypothesis that differ-
ences exist not only between the two different organs, but also
among different districts of the same organ.
The findings that in our experimental conditions we did not ob-
serve perivascular fibrosis in the kidney, that was instead present
at myocardial level, may depend on the increase in blood pres-
sure caused by CsA administration, that is perceived more by
myocardial intraparenchymal vessels, whereas the renal intra-
parenchymal arterioles are better protected.
In addition, the findings that in both kidney and heart the
antifibrotic action of C21 is major at the interstitial level, where
inflammatory infiltrates are concentrated, further suggests that
the antifibrotic action of C21 is mediated by an anti-inflammatory
mechanisms. In fact, the decrease of tissue fibrosis is present only
in the long-term treatment with C21, when a complete reduction
of the inflammatory cell infiltration has been achieved, whereas
it is not evident in the short-term treatment, in the presence of
still high inflammatory cell infiltrates.
In summary, in the present study we have shown that stimula-
tion of the protective arm of the renin angiotensin system, through
the selective agonist of AT-2 receptors C21, counteract tubulo-
interstitial fibrosis, the most potent predictor of the progression
of renal diseases.
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